High blood pressure (BP) is the leading risk factor for cardiovascular disease (CVD), with strong evidence supporting its causal role. The distribution of BP in the population has shifted to the right, indicating that many individuals have BP levels higher than what is considered normal. This shift is linked to increased CVD risk, including heart failure, stroke, and chronic kidney disease. Observational studies and clinical trials show that lowering BP reduces CVD risk, and the benefits align with those predicted from BP risk relationships in cohort studies. Prevention of age-related BP increases could significantly reduce vascular consequences of aging. Intensive treatment of established hypertension would reduce a large portion of the population burden of BP-related CVD. The study highlights that BP is a major modifiable risk factor for CVD, with high BP levels being more prevalent than previously thought. The distribution of BP in unacculturated populations is significantly lower than in acculturated societies, suggesting that traditional BP thresholds may not accurately reflect biological normality. This discrepancy may lead to underestimation of BP's role in CVD. The study also emphasizes that BP is a key factor in long-term CVD outcomes, such as heart failure, atrial fibrillation, and dementia. Clinical trials, including the Systolic Hypertension in the Elderly Program (SHEP) and Systolic Blood Pressure Intervention Trial (SPRINT), demonstrate that BP lowering significantly reduces CVD events. Meta-analyses of randomized controlled trials confirm that BP lowering is effective in preventing CVD. The study also notes that BP is a major risk factor for CVD, and its reduction can prevent many CVD events, especially in individuals without established CVD. The study concludes that BP is the primary cause of CVD, and reducing BP can significantly reduce the burden of CVD. It calls for greater attention to preventing age-related increases in BP, in addition to managing established hypertension. The findings support the need for comprehensive approaches to improve CVD risk factors at all life stages.High blood pressure (BP) is the leading risk factor for cardiovascular disease (CVD), with strong evidence supporting its causal role. The distribution of BP in the population has shifted to the right, indicating that many individuals have BP levels higher than what is considered normal. This shift is linked to increased CVD risk, including heart failure, stroke, and chronic kidney disease. Observational studies and clinical trials show that lowering BP reduces CVD risk, and the benefits align with those predicted from BP risk relationships in cohort studies. Prevention of age-related BP increases could significantly reduce vascular consequences of aging. Intensive treatment of established hypertension would reduce a large portion of the population burden of BP-related CVD. The study highlights that BP is a major modifiable risk factor for CVD, with high BP levels being more prevalent than previously thought. The distribution of BP in unacculturated populations is significantly lower than in acculturated societies, suggesting that traditional BP thresholds may not accurately reflect biological normality. This discrepancy may lead to underestimation of BP's role in CVD. The study also emphasizes that BP is a key factor in long-term CVD outcomes, such as heart failure, atrial fibrillation, and dementia. Clinical trials, including the Systolic Hypertension in the Elderly Program (SHEP) and Systolic Blood Pressure Intervention Trial (SPRINT), demonstrate that BP lowering significantly reduces CVD events. Meta-analyses of randomized controlled trials confirm that BP lowering is effective in preventing CVD. The study also notes that BP is a major risk factor for CVD, and its reduction can prevent many CVD events, especially in individuals without established CVD. The study concludes that BP is the primary cause of CVD, and reducing BP can significantly reduce the burden of CVD. It calls for greater attention to preventing age-related increases in BP, in addition to managing established hypertension. The findings support the need for comprehensive approaches to improve CVD risk factors at all life stages.